Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:1798 |
| Name | pancreatic endocrine carcinoma |
| Definition | An islet cell tumor that has_material_basis_in epithelial cells. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Xrefs |
SNOMEDCT_US_2023_03_01:254612002
|
| Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer islet cell tumor pancreatic endocrine carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| BRAF K601E | Trametinib | pancreatic endocrine carcinoma | predicted - resistant | detail... |
| BRAF K601E | Dabrafenib + Trametinib | pancreatic endocrine carcinoma | predicted - resistant | detail... |
| BRAF V600E | Vemurafenib | pancreatic endocrine carcinoma | predicted - sensitive | detail... |
| VHL inact mut | Belzutifan | pancreatic endocrine carcinoma | sensitive | detail... |
| BRAF V600E | Cobimetinib + Vemurafenib | pancreatic endocrine carcinoma | predicted - sensitive | detail... |
| BRAF V600E | Dabrafenib + Trametinib | pancreatic endocrine carcinoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01466036 | Phase II | Cabozantinib | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | Completed | USA | 0 |
| NCT02077933 | Phase I | Alpelisib + Everolimus Alpelisib + Everolimus + Exemestane | Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | Completed | USA | NLD | ITA | HUN | GBR | FRA | ESP | DEU | 1 |
| NCT02101918 | Phase II | Aflibercept | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
| NCT02108782 | Phase II | Dovitinib | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Withdrawn | 0 | |
| NCT02230176 | Phase II | Sunitinib Lutetium Lu 177 dotatate | Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM) | Completed | FRA | 0 |
| NCT02273752 | Phase II | Everolimus | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | Terminated | USA | 0 |
| NCT02315625 | Phase II | Everolimus Sunitinib | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | Terminated | USA | 0 |
| NCT02575300 | Phase II | Ibrutinib | Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | Completed | USA | 0 |
| NCT02687958 | Phase II | Everolimus | Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin | Unknown status | ITA | 0 |
| NCT02893930 | Phase II | Sapanisertib | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | Completed | USA | 0 |
| NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Completed | USA | GBR | 0 |
| NCT03043664 | Phase Ib/II | Lanreotide acetate + Pembrolizumab | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET) | Completed | USA | 0 |
| NCT03049189 | Phase III | 177Lu-edotreotide Everolimus | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | 1 |
| NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
| NCT03411915 | Phase I | XmAb18087 | A Study of XmAb18087 in Subjects With NET and GIST | Completed | USA | 0 |
| NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Unknown status | FRA | 0 |
| NCT03670030 | Phase II | Nab-rapamycin | A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System | Terminated | USA | 0 |
| NCT03870399 | Phase II | Tamoxifen | Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET) | Completed | USA | BRA | 0 |
| NCT03879694 | Phase I | Octreotide + Sargramostim + SurVaxM | Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors | Completed | USA | 0 |
| NCT03891784 | Phase II | Abemaciclib | Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
| NCT03901378 | Phase II | Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | Withdrawn | USA | 0 |
| NCT03972488 | Phase III | Octreotide acetate Lutetium Lu 177 dotatate + Octreotide acetate | Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
| NCT03980925 | Phase II | Carboplatin + Etoposide + Nivolumab | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | Completed | ESP | 0 |
| NCT04427787 | Phase II | Cabozantinib + Lanreotide acetate | A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) | Unknown status | ITA | 0 |
| NCT04525638 | Phase II | Lutetium Lu 177 dotatate + Nivolumab | A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours | Unknown status | ESP | 0 |
| NCT04919226 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin 177Lu-edotreotide Everolimus Capecitabine + Temozolomide | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 2 |
| NCT05053854 | Phase I | Lutetium Lu 177 dotatate + Talazoparib | PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (PARLuNET) | Recruiting | AUS | 0 |
| NCT05247905 | Phase II | Lutetium Lu 177 dotatate Capecitabine + Temozolomide | Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
| NCT05249114 | Phase I | Cabozantinib + Lutetium Lu 177 dotatate | Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
| NCT05262556 | Phase I | Ipilimumab + Nivolumab + Thymoquinone | TQ (Thymoquione) Formula With Nivolumab and Ipilimumab in Gastroenteropancreatic Neuroendocrine Carcinomas | Active, not recruiting | USA | 0 |
| NCT05364944 | Phase I | Debio 4126 + Lanreotide acetate Debio 4126 + Octreotide acetate | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01) | Terminated | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | 0 |
| NCT05477576 | Phase III | Everolimus Lanreotide acetate RYZ101 Sunitinib Octreotide acetate | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1) | Recruiting | USA | NLD | FRA | ESP | CAN | BRA | BEL | 1 |
| NCT05554003 | Phase II | Temozolomide | Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study (MeTe) | Recruiting | ITA | 0 |
| NCT05568017 | Phase II | Y-90-DOTATOC | Neoadjuvant PRRT With Y-90-DOTATOC in pNET | Terminated | ITA | 0 |
| NCT05599984 | Phase I | ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | Active, not recruiting | USA | ITA | ISR | FRA | ESP | DEU | AUS | 3 |
| NCT05610826 | Phase Ib/II | Lutetium Lu 177 dotatate | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | Withdrawn | USA | 0 |
| NCT05652686 | Phase I | PT217 | A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Recruiting | USA | 0 |
| NCT05687123 | Phase I | Lutetium Lu 177 dotatate + Sunitinib | Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors | Recruiting | USA | CAN | 0 |
| NCT05701241 | FDA approved | Lanreotide acetate Octreotide acetate | Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA) | Recruiting | NLD | BEL | 0 |
| NCT05746208 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | Recruiting | USA | 0 |
| NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
| NCT05987176 | Phase II | Lutetium Lu 177 dotatate | Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS) | Terminated | GBR | 0 |
| NCT05988918 | Phase II | CEP-11981 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | Recruiting | USA | 0 |
| NCT05997056 | Phase II | Nab-rapamycin | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | Recruiting | USA | 0 |
| NCT06016855 | FDA approved | Lutetium Lu 177 dotatate | Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors | Recruiting | USA | 0 |
| NCT06202066 | Phase II | Montanide ISA 51 + Sargramostim + SurVaxM + Temozolomide | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas | Recruiting | USA | 0 |
| NCT06395402 | Phase II | Lutetium Lu 177 dotatate | 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID) | Recruiting | USA | 0 |
| NCT06943755 | Phase II | XL092 Everolimus | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (STELLAR-311) | Recruiting | USA | POL | GBR | ESP | DEU | CAN | AUT | AUS | 3 |
| NCT07006727 | Phase I | 225Ac-ETN029 | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | Recruiting | USA | CAN | 1 |
| NCT07070232 | Phase Ib/II | BNT327 + YL202 YL202 Itraconazole + YL202 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | BEL | AUS | 0 |